Colorectal cancer pathophysiology

Saliba F, Hagipantelli R, Misset JL, Bastian G, Vassal G, Bonnay M, Herait P, Cote C, Mahjoubi M, Mignard D, Cvitkovic E. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer a prospective assessment. J Clin Oncol 1998 16(8) 2745-51. 

Not surprisingly, disturbance in the KP has been implicated in a number of diseases, and pharmacological intervention has thus potential for treatment. The immunosuppressive effects of the KP metabolites in the periphery are used in the treatment of multiple sclerosis (MS), where synthetic kynurenines are undergoing clinical development. Furthermore, IDO inhibitors are in preclinical development to treat cancers, for example, ovarian and colorectal [34]. This has been reviewed extensively elsewhere [3, 35], and the focus of the discussion in this review will be on the role of KP metabolites in brain pathophysiology. 

---